IceCure Medical Ltd – NASDAQ:ICCM

Add to watchlist

$0.876

-0.24

-21.83%

Market closed

Open in about 16 hours

+49.33%

month

+49.33%

quarter

+14.29%

year

Market Cap	61.74M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.31

Revenue	3.32M
EBITDA	-15.08M
Income	-14.61M
Revenue Q/Q	3.71%
Revenue Y/Y	8.97%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-454.13%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

IceCure Medical Ltd Stock Forecast

M Q Y

Last Year

$2.5

Potential upside: 185.55%

Analysts Price target
Financials & Ratios estimates

IceCure Medical Ltd (NASDAQ:ICCM): Profit margin
Jun 2023	937K	-3.88M	-415.05%
Sep 2023	327K	-4M	-1223.24%
Dec 2023	1.32M	-3.15M	-238.65%
Mar 2024	736.35K	-3.57M	-485.73%

IceCure Medical Ltd (NASDAQ:ICCM): Earnings per share (EPS)
2023-11-15	-0.09	-0.09
2024-04-03	-0.07	-0.07
2024-05-28	-0.08	-0.08

IceCure Medical Ltd (NASDAQ:ICCM): Debt to assets
Jun 2023	22693000	4.25M	18.75%
Sep 2023	19421000	4.63M	23.86%
Dec 2023	16274188	4.21M	25.88%
Mar 2024	15907253	4.37M	27.52%

IceCure Medical Ltd (NASDAQ:ICCM): Cash Flow
Jun 2023	-3.62M	1.15M	0
Sep 2023	-3.31M	4.20M	15K
Dec 2023	-2.85M	9.02M	69.32K
Mar 2024	-2.82M	486.60K	2.81M

IceCure Medical Ltd alternative data

IceCure Medical Ltd (NASDAQ:ICCM): Employee count
Aug 2023	65
Sep 2023	65
Oct 2023	65
Nov 2023	65
Dec 2023	65
Jan 2024	65
Feb 2024	65
Mar 2024	65
Apr 2024	65
May 2024	71
Jun 2024	71
Jul 2024	71

IceCure Medical Ltd
Hedge Funds Holdings Q1 2023

0.10% -0.33%

of ICCM is owned by hedge funds

4 -4

hedge funds hold ICCM stock

35.44K -122.45K

shares is hold by hedge funds

ICCM hedge funds holdings changes

IceCure Medical Ltd
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 28 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 3 Apr 2024	Q4 2023 Earnings Call Transcript
Q3 2023 15 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 14 Aug 2023	Q2 2023 Earnings Call Transcript

ICCM earnings call transcripts

IceCure Medical Ltd
Latest News

Monday, 16 December 2024
08:30	Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting	prnewswire.com
Tuesday, 26 November 2024
13:46	IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:41	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
08:30	IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation	prnewswire.com
Monday, 25 November 2024
08:30	IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office	prnewswire.com
Wednesday, 20 November 2024
08:30	IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024	prnewswire.com
Tuesday, 19 November 2024
08:30	IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health	prnewswire.com
Friday, 8 November 2024
07:00	FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer	prnewswire.com
Tuesday, 29 October 2024
08:30	Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders	prnewswire.com
Thursday, 11 July 2024
14:25	IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint	zacks.com
Tuesday, 9 July 2024
08:30	European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer	prnewswire.com
Wednesday, 3 July 2024
12:50	IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod	zacks.com
Monday, 1 July 2024
08:30	U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes	prnewswire.com
Tuesday, 18 June 2024
08:30	IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024	prnewswire.com
Wednesday, 12 June 2024
08:30	Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	prnewswire.com
Tuesday, 4 June 2024
13:01	IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade	zacks.com
08:30	FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	prnewswire.com
Tuesday, 28 May 2024
17:06	IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript	seekingalpha.com
08:30	IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	prnewswire.com
Tuesday, 21 May 2024
08:53	IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	prnewswire.com
08:30	IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	prnewswire.com
Monday, 20 May 2024
08:30	IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	prnewswire.com
Tuesday, 7 May 2024
08:30	Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	prnewswire.com
Thursday, 18 April 2024
12:10	IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA	Zacks Investment Research
Wednesday, 3 April 2024
13:20	IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 28 November 2023
13:41	5 Investors Betting Big on IceCure Medical (ICCM) Stock	InvestorPlace
Wednesday, 15 November 2023
10:33	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Wednesday, 8 November 2023
08:00	IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023	PRNewsWire
Friday, 22 September 2023
08:00	Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023	PRNewsWire
Monday, 14 August 2023
16:05	IceCure Medical Ltd (ICCM) Q2 2023 Earnings Call Transcript	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of IceCure Medical Ltd stock today?

One share of IceCure Medical Ltd stock can currently be purchased for approximately $0.88.
When is IceCure Medical Ltd's next earnings date?

Unfortunately, IceCure Medical Ltd's (ICCM) next earnings date is currently unknown.
Does IceCure Medical Ltd pay dividends?

No, IceCure Medical Ltd does not pay dividends.
How much money does IceCure Medical Ltd make?

IceCure Medical Ltd has a market capitalization of 61.74M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.67% to 3.23M US dollars. IceCure Medical Ltd made a loss 14.65M US dollars in net income (profit) last year or -$0.08 on an earnings per share basis.
What is IceCure Medical Ltd's stock symbol?

IceCure Medical Ltd is traded on the NASDAQ under the ticker symbol "ICCM".
What is IceCure Medical Ltd's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of IceCure Medical Ltd?

Shares of IceCure Medical Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does IceCure Medical Ltd have?

As Jul 2024, IceCure Medical Ltd employs 71 workers, which is 9% more then previous quarter.
When IceCure Medical Ltd went public?

IceCure Medical Ltd is publicly traded company for more then 4 years since IPO on 26 Aug 2021.
What is IceCure Medical Ltd's official website?

The official website for IceCure Medical Ltd is icecure-medical.com.
How can i contact IceCure Medical Ltd?

IceCure Medical Ltd can be reached via phone at +972 4 623 0333.
What is IceCure Medical Ltd stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for IceCure Medical Ltd in the last 12 months, the avarage price target is $2.5. The average price target represents a 185.55% change from the last price of $0.88.

IceCure Medical Ltd

icecure-medical.com

Exchange:

NASDAQ

Full time employees:

Industry:

Medical - Devices

Sector:

Healthcare

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

+972 4 623 0333

7 Ha’Eshel Street
Caesarea, 3079504

CIK: 0001584371
ISIN: IL0011224156
CUSIP: M53071136